Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
3 Strong Oncology & Specialty Momentum: Beyond neuroscience, BMSs growth portfolio delivered $6.9B, led by: OPDIVO (nivolumab) US HCP: $2.5B (+8%) Breyanzi (lisocabtagene maraleucel) HCP: $359M (+58%) CAMZYOS (mavacamten) US HCP: $296M (+88%) These results reinforce BMSs transformation into a data-rich, diversified biopharma, with pivotal readouts expected in 2026 across fibrosis, multiple myeloma, and autoimmune indications
References Jalleh RJ, Plummer MP, Marathe CS, et al
However, despite these trials, BPC-157 lacks FDA approval, raising concerns about its safety and efficacy due to insufficient clinical testing
[Abstract]2022 Aug;54:102392
Heterogeneous Expression of Gamma-Aminobutyric Acid and Gamma-Aminobutyric Acid-Associated Receptors and Transporters in the Rat Suprachiasmatic Nucleus. The Journal of Comparative Neurology, vol
It can also be compounded for injection
